These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 26380149)

  • 21. Reversal of Anticoagulation and Management of Bleeding in Patients on Anticoagulants.
    Dhakal P; Rayamajhi S; Verma V; Gundabolu K; Bhatt VR
    Clin Appl Thromb Hemost; 2017 Jul; 23(5):410-415. PubMed ID: 27789605
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Management of bleeding associated with direct oral anticoagulants: update on reversal strategies].
    Enríquez A; Baranchuk A; Corbalán R
    Rev Med Chil; 2019; 147(1):73-82. PubMed ID: 30848768
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [New - direct oral anticoagulants: actual review].
    Michalcová J; Penka M; Buliková A; Zavřelová J; Štěpařová A
    Vnitr Lek; 2016; 62(10):805-813. PubMed ID: 27900867
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Non-Vitamin K Oral Anticoagulants Associated Bleeding and Its Antidotes.
    Steiner T; Köhrmann M; Schellinger PD; Tsivgoulis G
    J Stroke; 2018 Sep; 20(3):292-301. PubMed ID: 30309225
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Reversal of Novel Anticoagulants in Emergent Surgery and Trauma: A Comprehensive Review and Proposed Management Algorithm.
    Palaiodimos L; Miles J; Kokkinidis DG; Barkolias C; Jonnalagadda AK; Papaconstantinou D; Frountzas M; Misiakos EP; Schizas D
    Curr Pharm Des; 2018; 24(38):4540-4553. PubMed ID: 30585542
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Reversal of oral anticoagulation in patients with acute intracerebral hemorrhage.
    Kuramatsu JB; Sembill JA; Huttner HB
    Crit Care; 2019 Jun; 23(1):206. PubMed ID: 31171018
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Relative efficacy and safety of non-Vitamin K oral anticoagulants for non-valvular atrial fibrillation: Network meta-analysis comparing apixaban, dabigatran, rivaroxaban and edoxaban in three patient subgroups.
    Lip GY; Mitchell SA; Liu X; Liu LZ; Phatak H; Kachroo S; Batson S
    Int J Cardiol; 2016 Feb; 204():88-94. PubMed ID: 26655548
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Strategies of neutralization of the direct oral anticoagulants effect: review of the literature.
    Jourdi G; Le Bonniec B; Gouin-Thibault I
    Ann Biol Clin (Paris); 2019 Feb; 77(1):67-78. PubMed ID: 30591426
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antidotes to non-vitamin K oral anticoagulants: necessary or not?
    Proietti M; Lip GY
    Expert Opin Pharmacother; 2015; 16(11):1573-6. PubMed ID: 26077323
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Reversal of direct oral anticoagulants: a practical approach.
    Shih AW; Crowther MA
    Hematology Am Soc Hematol Educ Program; 2016 Dec; 2016(1):612-619. PubMed ID: 27913536
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Reversal strategies for non-vitamin K antagonist oral anticoagulants].
    Larsen FU; Hvas AM; Grove EL
    Ugeskr Laeger; 2016 Oct; 178(40):. PubMed ID: 27697119
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Using new oral anticoagulants in patients undergoing major orthopedic surgery.
    Bass AR
    Curr Rheumatol Rep; 2015 Apr; 17(4):25. PubMed ID: 25854486
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Oral anticoagulants and status of antidotes for the reversal of bleeding risk.
    Ebright J; Mousa SA
    Clin Appl Thromb Hemost; 2015 Mar; 21(2):105-14. PubMed ID: 25115762
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mechanisms of action and clinical use of specific reversal agents for non-vitamin K antagonist oral anticoagulants.
    Andresen K; Atar D; Gjertsen E; Ghanima W; Roseth S; Johansen OE
    Scand Cardiovasc J; 2018 Jun; 52(3):156-162. PubMed ID: 29569500
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effectiveness and Safety of Non-vitamin K Antagonist Oral Anticoagulants for Atrial Fibrillation and Venous Thromboembolism: A Systematic Review and Meta-analyses.
    Almutairi AR; Zhou L; Gellad WF; Lee JK; Slack MK; Martin JR; Lo-Ciganic WH
    Clin Ther; 2017 Jul; 39(7):1456-1478.e36. PubMed ID: 28668628
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparative effectiveness of warfarin, dabigatran, rivaroxaban and apixaban in non-valvular atrial fibrillation: A nationwide pharmacoepidemiological study.
    Kjerpeseth LJ; Selmer R; Ariansen I; Karlstad Ø; Ellekjær H; Skovlund E
    PLoS One; 2019; 14(8):e0221500. PubMed ID: 31449560
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Reversal of Dabigatran with Idarucizumab in Acute Subarachnoid Hemorrhage.
    Balakumar J; Santiago R; Supino M
    Clin Pract Cases Emerg Med; 2017 Nov; 1(4):349-353. PubMed ID: 29849330
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Andexanet: Effectively Reversing Anticoagulation.
    Lippi G; Sanchis-Gomar F; Favaloro EJ
    Trends Pharmacol Sci; 2016 Jun; 37(6):413-414. PubMed ID: 27048885
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Administration of idarucizumab in spontaneous intracerebral hemorrhage under dabigatran-therapy].
    Bereczki D; Szilágyi G; Kakuk I; Szakács Z; May Z
    Ideggyogy Sz; 2017 Sep; 70(9-10):349-353. PubMed ID: 29870627
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparative study of hemorrhagic and ischemic complications among anticoagulants in patients undergoing cryoballoon ablation for atrial fibrillation.
    Okishige K; Nakamura T; Aoyagi H; Kawaguchi N; Yamashita M; Kurabayashi M; Suzuki H; Asano M; Shimura T; Yamauchi Y; Sasano T; Hirao K
    J Cardiol; 2017 Jan; 69(1):11-15. PubMed ID: 27160710
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.